
REHOVOT, Israel, Nov. 20, 2026 (GLOBE NEWSWIRE) -- Purple Biotech Ltd. ("Purple Biotech" or the "Company") (NASDAQ/TASE: PPBT), a biotechnology company developing a next-generation immunotherapy platform designed to maximize anti-cancer potency while minimizing toxicity, today announced the presentation of preclinical data on IM1240, the lead capped tri-specific antibody from its CAPTN-3 platform, in a plenary oral session at the 38th EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics (ENA 2026), being held November 18-20, 2026, in Barcelona, Spain.
CAPTN-3 is Purple Biotech's platform of capped tri-specific antibodies. Each antibody combines three arms in a single molecule: a targeting arm that binds a cancer-associated antigen and can be exchanged to address different cancers; a CD3 arm that engages T cells; and an NKG2A arm that engages NK cells and blocks an inhibitory immune checkpoint. The CD3 arm is capped: it is designed to remain inactive in circulation and to be uncapped by proteases in the tumor microenvironment, confining T-cell activation to the cancer and, based on preclinical data, expanding the therapeutic window compared with non-capped T-cell engagers. IM1240, the platform's lead candidate, targets 5T4.
The findings were presented in a plenary oral session by Amir Horowitz, Ph.D., Associate Professor of Immunology and Immunotherapy and Oncological Sciences at the Icahn School of Medicine at Mount Sinai, and a member of the Marc and Jennifer Lipschultz Precision Immunology Institute and The Tisch Cancer Institute.